

UNITED STATES PATENT AND TRADEMARK OFFICE

BEFORE THE PATENT TRIAL AND APPEAL BOARD

MURRAY & POOLE ENTERPRISES LTD.,

Petitioner,

v.

INSTITUT DE CARDIOLOGIE DE MONTREAL,

Patent Owner.

Case IPR2023-01064

Patent 11,400,063

PATENT OWNER'S UPDATED EXHIBIT LIST

Pursuant to 37 C.F.R. §§ 42.63(e) and 42.64(b)(2), Patent Owner Institut de Cardiologie de Montréal hereby submits a corrected listing of Patent Owner's exhibits. Exhibits 2054-2074 were filed on April 9, 2024.

Exhibit	Description
2001	Declaration of Hossein Ardehali, M.D.
2002	Australia New Zealand Clinical Trials Registry, The LoDoCo Trial: The effect of low dose colchicine on the natural history of patients with stable coronary artery disease (ACTRN12610000293066) (2014) ("LoDoCo Trial")
2003	Clinicaltrials.gov identifier NCT01327846, <i>Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events) (CANTOS)</i> , https://clinicaltrials.gov/study/NCT01327846?titles=CANTOS&rank=1 (last accessed Oct. 4, 2023) ("CANTOS")
2004	Clinicaltrials.gov identifier NCT02551094, <i>Colchicine Cardiovascular Outcomes Trial (COLCOT)</i> , https://clinicaltrials.gov/study/NCT02551094?titles=COLCOT&rank=1 (last accessed Oct. 4, 2023) ("COLCOT")
2005	M. Imazio et al., <i>Colchicine in addition to conventional therapy for acute pericarditis: results of the Colchicine for acute Pericarditis (COPE) trial</i> , 112 CIRCULATION 2012-2016 (2005) ("Imazio 2005a")
2006	M. Imazio et al., <i>Colchicine as first choice therapy for recurrent pericarditis: results of the CORE (Colchicine for Recurrent pericarditis) trial</i> , 165 ARCH. INTERN. MED. 1987-1991 (2005) ("Imazio 2005b")
2007	M. Imazio et al., <i>Colchicine for recurrent pericarditis (CORP): a randomized trial</i> , 155 ANN. INTERN. MED. 409-414 (2011) ("Imazio 2011")
2008	Maria Isabel Lopes et al., <i>Beneficial effects of colchicine for moderate to severe COVID-19: a randomized double-blinded, placebo-controlled</i>

	<i>clinical trial</i> , 7 RMD Open 1455 (2021)
2009	J.H. O’Keefe et al., <i>Ineffectiveness of colchicine for the prevention of restenosis after coronary angioplasty</i> , 19 J. AM. COLL. CARDIOL. 1597-1600 (1992) (“O’Keefe”)
2010	Terkeltaub et al., <i>High versus low dosing of oral colchicine for early acute gout flare: Twenty-four hour outcome of the first multicenter, randomized, double-blinded, placebo-controlled, parallel-group, dosecomparison colchicine study</i> , 62 ARTHRITIS & RHEUMATOLOGY 1060-1068 (2010)
2011	Declaration of Jean-Claud Tardif, M.D.
2012	COLCOT Site 1004 Research Agreement
2013	COCLOT Leschke Site Research Agreement
2014	COLCOT Berube Site Research Agreement
2015	COLCOT Fung Site Research Agreement
2016	Funding Approval Letter from Quebec Ministry of Finance
2017- 2053	RESERVED
2054	Nina C. Raju, et al., <i>Effect of colchicine compared with placebo on high sensitivity C-reactive protein in patients with acute coronary syndrome or acute stroke: a pilot randomized controlled trial</i> , 33 J. TROMB. THROMBOLYSIS 88-94 (2011) (“Raju”)
2055	Mariama Akodad, et al., <i>COLIN trial: Value of colchicine in the treatment of patients with acute myocardial infarction and inflammatory response</i> , 110 ARCH. CARDIO. DIS. 395-402 (2017) (“Akodad”)
2056	David C. Tong & Jamie Layland, <i>Colchicine in Patients with Acute Coronary Syndrome: The Australian COPS Randomized Clinical Trial</i> , 142 CIRC. 1890-1900 (2020) (“Tong”)

2057	Abdul Q. Nawabi, et al., <i>Is Colchicine a New Game-Changer in Patients with Acute Coronary Syndrome?</i> , 14 CUREUS 1-5 (2022) (“Nawabi”)
2058	Jens Jakob Thune, et al., <i>Predictors and prognostic impact of recurrent myocardial infarction in patients with left ventricular dysfunction, heart failure, or both following a first myocardial infarction</i> , 13 EUR. J. HEART FAILURE 148-153 (2010) (“Thune”)
2059	Alexander E. Merkler, et al., <i>Duration of Heightened Ischemic Stroke Risk After Acute Myocardial Infarction</i> , 7 J. AM. HEART ASSOC. 1-6 (2018) (“Merkler”)
2060	Amit Kumar Shrivastava, et al., <i>C-reactive protein, inflammation and coronary heart disease</i> , 67 EGYPTIAN HEART J. 89-97 (2014) (“Shrivastava”)
2061	Sonia S. Anand & Salim Yusuf, <i>C-reactive protein is a bystander of cardiovascular disease</i> , 31 EUR. HEART J. 2092-2097 (2010) (“Yusuf”)
2062	BMJ, <i>Association between C reactive protein and coronary heart disease: mendelian randomisation analysis based on individual participant data</i> , BMJ.COM 1-8 (2011) (“BMJ 2011”)
2063	C. Judkins, et al., <i>LoDoCo: LOw DOse COLchicine in Stable Coronary Artery Disease and the Effects on hs-CRP and Barchial Flow Mediated Dilation</i> , CSANZ Abstracts 2011, 20S HEART, LUNG, & CIRC. S36 (2011) (“Judkins”)
2064	Spyridon Deftereos, et al., <i>Colchicine Treatment for the Prevention of Bare-Metal Stent Restenosis in Diabetic Patients</i> , 61 J. AM. COLL. CARDIO. 1679-1685 (2013) (“Deftereos 2013”)
2065	S.M. Nidorf, et al., <i>Colchicine in Patients with Chronic Coronary Disease</i> , 383 N. ENG. J. MED. 1838-1847 (2020) (“Nidorf 2020”)
2066	Binita Shah, et al., <i>Effects of Acute Colchicine Administration Prior to Percutaneous Coronary Intervention: COLCHICINE-PCI Randomized Trial</i> , 13 CIRC. CARDIO. INTERV. 1-11 (2020) (“Shah”)
2067	As-filed Claims of U.S. Provisional Patent Application No. 62/935,865 (“the ’865 provisional application claims”)
2068	Declaration of Nadia Bouabdallaoui, M.D., Ph.D.
2069	Record History for NCT02551094 Colchicine Cardiovascular Outcomes Trial (COLCOT), https://clinicaltrials.gov/study/NCT02551094?intr=colchicine&rank=12&tab=history&a=10#oversight-card (last accessed Mar. 18, 2024)
2070	David C. Tong, et al., <i>Colchicine in Patients with Acute Coronary Syndrome: The Australian COPS Randomized Clinical Trial</i> , Circulation

	Online, https://doi.org/10.1161/CIRCULATIONAHA.120.050771 (2020) (“Tong Online Version”)
2071	Deposition Transcript of Dr. Paul Ridker, M.D., M.P.H.
2072	Supplemental Declaration of Hossein Ardehali, M.D., Ph.D.
2073	Peter W.F. Wilson, et al., <i>An International Model to Predict Recurrent Cardiovascular Disease</i> , 125 AM. J. MED. 695-703 (2012) (“Wilson”)
2074	Sang Hun Lee, et al., <i>Predictors of recurrent acute myocardial infarction despite successful percutaneous coronary intervention</i> , 37 KOREAN J. INTERN. MED. 777-785 (2022) (“Lee”)
2075	Institut de Cardiologie de Montreal’s Demonstrative Exhibits for Oral Argument

Respectfully submitted,

Date: October 10, 2024

By: /s/ Sailesh Patel
Sailesh K. Patel, Reg. No. 46,982
Lead Counsel for Patent Owner
Institut de Cardiologie de Montréal

CERTIFICATE OF SERVICE

Pursuant to 37 C.F.R. §§ 42.6(e) and 42.105(a), the undersigned certifies that on October 10, 2024, a copy of the foregoing Patent Owner's Corrected Exhibit List were served electronically via e-mail on the following:

Joanna Brougher (jbrougher@biopharmalaw.com)

Thomas Siepmann (tsiepmann@biopharmalaw.com)

Kevin Laurence (klaurence@lpiplaw.com)

Matthew Phillips (mphilips@lpiplaw.com)

Derek Meeker (dmeeker@lpiplaw.com)

Joe Hawkins (jhawkins@lpiplaw.com)

Petitioner has agreed to electronic service.

Dated: October 10, 2024

By: /s/ Matthew Wilkerson
Matthew T. Wilkerson
ARENTFOX SCHIFF LLP